We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 11, 2020

Cabazitaxel as Second-Line in Patients With HER2– Metastatic Breast Cancer Previously Treated With Taxanes

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
Phase 2 Study of Cabazitaxel as Second-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer Previously Treated With Taxanes—A Hellenic Cooperative Oncology Group (HeCOG) Trial
Br. J. Cancer 2020 Aug 01;123(3)355-361, A Koutras, F Zagouri, GA Koliou, E Psoma, I Chryssogonidis, G Lazaridis, D Tryfonopoulos, A Kotsakis, E Res, NK Kentepozidis, E Razis, A Psyrri, G Koumakis, HP Kalofonos, MA Dimopoulos, G Fountzilas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading